anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an inclusion compound of alpha crystal imatinib. The inclusion compound of alpha crystal imatinib is prepared by selecting cyclodextrin or derivatives thereof as an inclusion material and is characterized by comprising 0.1-0.3wt% of alpha crystal imatinib and 97.0-99.9wt% of cyclodextrin or derivatives thereof. In the preparation of the inclusion compound, a solvent method and a grinding method can be adopted. As the inclusion compound is prepared by adopting the cyclodextrin or derivatives thereof to include the alpha crystal imatinib, the sensitivity of the alpha crystal imatinib to light, temperature and heat is overcome, and the instability problem of the alpha crystal imatinib is solved. Liquid preparations, semi-solid preparations or solid preparations further prepared from the inclusion compound respectively have improved stability and convenience in operation. The inclusion compound is simple in preparation process, has no need of special requirements on preparation package and storage conditions, and is a novel alpha crystal imatinib preparation which has better liquidity, higher stability and lower moisture absorption and is suitable for clinical use.
INTRODUCTION: Anastomotic leakage is a major concern following total mesorectal excision for rectal cancer, affecting oncological outcomes, morbidity an treatment costs. Body composition has been suggested to influence anastomotic leakage rates. However, literature on how body composition impact anastomotic leakage rates is conflicting. This systematic review aims to evaluate the role of computed tomography derived body composition metrics on anastomotic leakage rates in rectal cancer patients.
METHODS: Databases PubMed/MEDLINE, Cochrane Library, web of science, and EMBASE, will be systematically searched for papers from January 2010 onwards. Study selection, data collection and quality assessment will be independently performed by three research fellows. Outcomes described in three or more studies will be included in the meta-analysis. The Q-test and I2 statistic will be used to assess statistical heterogeneity between studies. Publication bias will be examined by visual inspection of funnel plots and quantified by Egger's test. Sensitivity analyses will be conducted to examine the robustness of the meta-analysis. Reporting of the findings will be in line with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.
CONCLUSIONS: This systematic review will synthesize the current evidence and will identify knowledge gaps. Results of the systematic review will aid health care professional in pre-operative decision making and will be distributed through a peer-reviewed publication and presentation of results at international meetings.
TRIAL REGISTRATION: PROSPERO protocol number: CRD42023471537.
The present invention relates to pairs of oligonucleotides or oligonucleotide analogue sequences capable of hybridising to one another, wherein one of or both oligonucleotides/oligonucleotide analogues comprise an intercalator pseudonucleotide. Intercalator pseudonucleotides according to the invention are capable of being incorporated into the phosphate backbone of a nucleic acid and comprise an intercalator comprising at least one essentially flat conjugated system, which is capable of co-stacking with nucleobases of a nucleic acid. Furthermore, the invention relates to oligonucleotide analogues, comprising intercalator pseudonucleotide(s). The invention also relates to methods of detecting hybridisation between a target nucleic acid and an oligonucleotide analogue comprising at least one intercalator pseudonucleotide. Furthermore, methods for amplification of nucleic acids or nucleic acid analogues, comprising using an oligonucleotide analogues comprising an intercalator pseudonucleotide capable of hybridizing with the nucleic acid sequence, which is desirable to amplify are described. In addition the invention relates to methods of modulating transcription of genes.
FIELD: medicine.SUBSTANCE: method involves doing therapeutic exercises and pulsed ultrasonic therapy at a pulse length of 10 ms. That is combined with the magnetic stimulation of the shoulder girdle muscles: m. trapezius m. deltoideus, m. supraspinatus, m. infraspinatus on the involved side. That involves the exposure in accordance with a stable technique with using paired pulses of the length of 220±20 mcs at a pulse repetition frequency of 25±5 pulse/min and a pulse-to-pulse spacing of 80 ms for 3 min per one field. The exposure intensity is 70-90% of the maximum magnetic induction amplitude 1,300 mT. The total length of the procedure is 12 minutes. Then 30 minutes later, mud therapy is conducted by applications on the involved shoulder joint. A mud cake temperature makes 38-40 degrees, and the length of the exposure makes 20 minutes. The mud therapy is followed by ultrasonic therapy. The exposure covers the rotator cuff and attachment points of the tendons - m. supraspinatus, m. infraspinatus, m. teres minor on the involved side. The exposure follows a labile technique at an intensity of 0.2-0.4 W/cmfor 2 minutes per each field at the total length of the procedure of 8 minutes. The procedures are daily. The therapeutic course is 8-10 procedures.EFFECT: method enables clinical effectiveness by recovering the motor activity of the involved extremity and prolongs the remission, prevents the progression of the biomechanical and neurodystrophic disorders, and formation of neurological complications.1 ex, 4 tbl, 1 dwg
PURPOSE:To obtain the novel catenin relating to an intercellular adhesive function, a gene coding the same, and to provide a method for using the same. CONSTITUTION:Neural alpha-catenin. A gene coding the same. A gene capable of being hybridized with the gene. A method for producing the neural alpha-catenin by producing the neural alpha-catenin by a genetic engineering method using these genes. A method for controlling an intercellular adhesive function with these genes. An antibody capable of specifically recognizing the neural alpha-catenin. The 906 amino acid sequence, the length of the gene and further the restriction enzyme map of the neural alpha-catenin were determined.
An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu ( Dromais Novae - Hollandiae ), an indigenous bird of Australia and New Zealand. The present invention also discloses therapeutic compositions comprising Emu Oil in combination with an extracellular product of  Bacillus coagulans  or  Pseudomonas lindbergii  strain, comprising a supernatant or filtrate of said culture suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. Additionally, the aforementioned therapeutic composition may also include an anti-microbial, anti-mycotic, and/or anti-viral agent. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions comprising Emu Oil in combination with an extracellular product of  Bacillus coagulans  or  Pseudomonas lindbergii  strain suitable for topical application to the skin or mucosal membranes of a mammal. Similarly, the aforementioned method may also employ a therapeutic composition additionally containing an anti-microbial, anti-mycotic, and/or anti-viral agent.
Intermittent fasting (IF) modifies cell- and tissue-specific immunometabolic responses that dictate metabolic flexibility and inflammation during obesity and type 2 diabetes (T2D). Fasting forces periods of metabolic flexibility and necessitates increased use of different substrates. IF can lower metabolic inflammation and improve glucose metabolism without lowering obesity and can influence time-dependent, compartmentalized changes in immunity. Liver, adipose tissue, skeletal muscle, and immune cells communicate to relay metabolic and immune signals during fasting. Here we review the connections between metabolic and immune cells to explain the divergent effects of IF compared with classic caloric restriction (CR) strategies. We also explore how the immunometabolism of metabolic diseases dictates certain IF outcomes, where the gut microbiota triggers changes in immunity and metabolism during fasting.
The extracellular matrix is a highly dynamic environment, and the precise temporal presentation of biochemical signals is critical for regulating cell behavior during development, healing, and disease progression. To mimic this behavior, we developed a modular DNA-based hydrogel platform to enable independent and reversible control over the immobilization of multiple biomolecules during in vitro cell culture. We combined reversible DNA handles with a norbornene-modified hyaluronic acid hydrogel to orthogonally add and remove multiple biomolecule-DNA conjugates at user-defined timepoints. We demonstrated that the persistent presentation of the cell adhesion peptide RGD was required to maintain cell spreading on hyaluronic acid hydrogels. Further, we discovered the delayed presentation of osteogenic growth peptide (OGP) increased alkaline phosphatase activity compared to other temporal variations. This finding is critically important when considering the design of OGP delivery approaches for bone repair. More broadly, this platform provides a unique approach to tease apart the temporal role of multiple biomolecules during development, regeneration, and disease progression.
Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-2, participants will be asked to only watch the rugby matches. They will not received any intervention.
Varicose veins are the prevalent vascular disorder that has conventionally been managed via risky postoperative wound infections and conventional surgery. While ultrasound-guided microwave ablation (UMA) has gained attention as a minimally invasive alternative, there is still a lack of research examining its comparative effectiveness. A prospective comparative investigation was undertaken in the Zhejiang region of China from January to November 2023, involving 140 patients who had received the diagnosis of primary varicose veins. An equal number of 70 patients underwent UMA and conventional surgery. Exclusion criteria for the study encompassed adult patients aged 18-65, with the exception of those who had undergone prior venous surgery, deep vein thrombosis or peripheral arterial disease. The demographical characteristics, procedural details and complication profiles of patients who developed postoperative wound infections within 30 days were analysed statistically. The outcomes demonstrated that postoperative wound infections were significantly diminished (5.7%) with UMA in comparison to conventional surgery (17.1%). In addition, the average duration of procedures and length of hospital stay for UMA patients were both reduced, although neither of these differences was found to be statistically significant (p > 0.05). Infection management, age and gender distribution of varicose veins were comparable between the two groups (p > 0.05). A significant inverse correlation was observed between the severity of varicose veins and postoperative outcomes, as determined by the regression analysis (p < 0.05). Using UMA to treat varicose veins showed promise as an alternative to conventional surgery, specifically in minimizing the incidence of postoperative wound infections. Additional research and clinical consideration are needed regarding the potential transition toward minimally invasive techniques in treatment of varicose veins, as suggested by these results.
The present invention relates to a methylene chloride fraction of a Foeniculum vulgare Gaertner fruit extract, which exhibits effects of ameliorating or treating dermatitis. More specifically, the present invention relates to a pharmaceutical composition containing a methylene chloride fraction of a Foeniculum vulgare Gaertner fruit extract which has excellent effects of treating inflammation in an animal model with dermatitis. In addition, the composition of the present invention is also outstanding in inhibition of the expression of proinflammatory mediators and proinflammatory cytokines and also inhibition of nuclear translocation of NF-κB p65. The present invention further relates to an external skin application composition therefor. According to the present invention, used in the composition is Foeniculum vulgare Gaertner which is an edible plant. Thus, the composition can be safely used since the composition does not cause cytotoxicity.
Provided are techniques, devices and systems that include monitoring a trend of blood glucose measurement values over a series of measurement cycles. A processor may identify a potential excursion outside a range of a target blood glucose measurement value setting of a user based on the monitored trend. In response to the identified potential excursion, an alert may be generated to the user to consume rescue carbohydrates. In addition, the disclosed techniques may include a processor that assesses the factors related to a potential impending hypoglycemic event for a user. Based on a result of the assessment of the factors, the processor may determine whether the user is approaching the potential impending hypoglycemic event for the user. In response to a determination that the user is approaching the potential impending hypoglycemic event for the user, a number of rescue carbohydrates to suggest for consumption by the user may be determined.
Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.
The present invention relates to the isolation of a new gene, des, which encodes a  M. tuberculosis  protein named DES. The des gene appears to be conserved among different Mycobacteria species. The amino acid sequence of the DES protein contains two sets of motifs that are characteristic of the active sites of enzymes from the class II diiron-oxo protein family. Among this family of proteins, DES shares significant homology with soluble stearoyl-ACP desaturases. DES is a highly antigenic protein, which is recognized by human sera from patients infected with  M. tuberculosis  and  M. leprae  but not by sera from tuberculous cattle. Thus, the DES protein provides a useful tool for the serodiagnostic analysis of tuberculosis.
New combinations (A) comprise (a) at least one precursor for 6-hydroxy-sphingenin based ceramide or 6-hydroxy-sphingenin based ceramide derivative, which is a substrate for 6-hydroxylase enzymes and (b) activator(s) for the 6-hydroxylase pathway. An independent claim is included for compositions comprising (A) in a physiologically acceptable medium. ACTIVITY : Dermatological. MECHANISM OF ACTION : 6-Hydroxylase pathway activator; stimulant of epidermal synthesis of ceramides based on 6-hydroxy-sphingenin. Addition of vitamin C at 50 Microg/ml to a culture medium for reconstructed epidermis increased the 6-hydroxy-sphingenin content after 6 days from ca. 1000 ng to ca. 5000 ng and reduced the sphingenin content after 6 days from ca. 14000 ng to ca. 4000 ng (all per mg of total lipids).
In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values. Discretionary use of intrathecal morphine may be used.
Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and pancreas) in dogs treated with azithromycin at doses which, expressed on the basis of mg/m2, are approximately equal to the recommended adult human dose, and in rats treated at doses approximately one-sixth of the recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs given daily doses of azithromycin ranging from 10 days to 30 days. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (30 mg/kg dose) at observed Cmax value of 1.3 mcg/mL (six times greater than the observed Cmax of 0.216 mcg/mL at the pediatric dose of 10 mg/kg). Similarly, it has been shown in the dog (10 mg/kg dose) at observed Cmax value of 1.5 mcg/mL (seven times greater than the observed same Cmax and drug dose in the studied pediatric population). On a mg/m2 basis, 30 mg/kg dose in the neonatal rat (135 mg/m2) and 10 mg/kg dose in the neonatal dog (79 mg/m2) are approximately 0.5 and 0.3 times, respectively, the recommended dose in the pediatric patients with an average body weight of 25 kg. Phospholipidosis, similar to that seen in the adult animals, is reversible after cessation of azithromycin treatment. The significance of these findings for animals and for humans is unknown.
APOKYN is indicated for subcutaneous administration only [see Warnings and Precautions (5.1)] and only by a multiple-dose APOKYN Pen with supplied cartridges. The initial dose and dose titrations should be performed by a healthcare provider. Blood pressure and pulse should be measured in the supine and standing position before and after dosing. 

A caregiver or patient may administer APOKYN if a healthcare provider determines that it is appropriate. Instruct patients to follow the directions provided in the Patients Instructions For Use. Because the APOKYN Pen has markings in milliliters (mL), the prescribed dose of APOKYN should be expressed in mL to avoid confusion.

Visually inspect the APOKYN drug product through the viewing window for particulate matter and discoloration prior to administration. The solution should not be used if discolored (it should be colorless), or cloudy, or if foreign particles are present. Rotate the injection site and use proper aseptic technique [see How Supplied/Storage and Handling (16) and Patient Counseling Information (17)] .
Self-exercise during hemodialysis reportedly prevents functional decline. This study aimed to assess the effects of exercise on physical function during hemodialysis. From September 2014 to March 2018, 35 elderly dialysis patients participated in an exercise program 3 times a week for 24 weeks during hemodialysis under staff supervision. The Short Physical Performance Battery and muscle strength test were used to measure physical function, and the Short Form Version 2 and Self-Rating Questionnaire for Depression were used to measure psychological function. For Short Physical Performance Battery, walking speed and standing time improved significantly. Other significant improvements were observed in both knee extension muscle strength and right side of grip strength. There was also an improving trend in both Short Form Version 2 and Self-Rating Questionnaire for Depression after the intervention compared with the baseline. A long-term supervised self-exercise program during dialysis led to maintenance and improvement of physical and psychological functioning in elderly dialysis patients.
Disclosed is a computer-implemented method of determining a hypersurface image from a tomographic image data set describing a tomographic image of an anatomical body part. The method encompasses a locally depth-of-view-corrected reconstruction of a volumetric data set (pre-operative image data, like CT or MRI image data), in order to e.g. augment volumetric image data onto e.g. a microscope view, or in the head-up display of the microscope. For the depth correction, a surface model of the actual anatomical surface of the anatomical body part is used which encompasses a hypersurface reconstruction pf the volumetric data set. Thus, the correct information related to the tissue at the current visible surface is overlaid.
Low back pain (LBP) is the leading musculoskeletal condition in burden of disease and years lived with disability. This high ranking is in large part due to the high prevalence of LBP. LBP is not only mechanically related to spinal pathophysiology (i.e., postural alterations, articular stiffness, or muscle weakness), but may also be influenced by psychosocial factors such as attitudes and beliefs. Multidisciplinary rehabilitation programs, which include biopsychosocial management, resulted in a better outcome. The aim of this project is to determine if the change in LBP-related knowledge and attitudes toward LBP are correlated with the change in LBP-related pain, disability, fear avoidance, and emotional states of depression, anxiety, and stress after three months. Secondly, the investigators will investigate the effect of adding LBP knowledge related education sessions to standard physical therapy treatment on patients' LBP knowledge, attitudes toward LBP, LBP-related pain, disability, fear avoidance, and emotional symptoms in comparison to standard physical therapy alone. 74 patients with LBP receiving standard physical therapy service for the first time will be interviewed and their knowledge and attitude about LBP will be collected at the baseline. After 3 months, the LBP related pain, emotional symptoms, and LBP disability will be collected. The patients will be allocated to "Experimental group" consist of 37 patients will take education sessions in addition to standard physical therapy for 12 sessions or "control group" consist of 37 patients take just standard physical therapy for the same number of sessions without education. Participants will be assessed at baseline and at 3 months follow up. Outcome measures include Arabic version of the Back Pain Attitudes (Back-PAQ), Low Back Pain Knowledge (LKQ) Questionnaires, Arabic version of Oswestry Disability Index (ODI) to assess the function, Visual Analogue Scale for pain intensity, Depression Anxiety Stress Scales (DASS-21) for emotional states, and Fear-Avoidance Beliefs Questionnaire (FABQ) for fear avoidance beliefs. Spearman correlation coefficient r will be used to investigate the correlation between change in LBP knowledge and attitude, and change in pain, disability, fear avoidance and emotional symptoms after three months. Independent sample t-test will be used to compare the knowledge, attitude, VAS, ODI, FABQ, and DASS- between the experimental group and control group.